Inotiv, Inc. - NOTV STOCK NEWS

Inotiv, Inc. (NASDAQ: NOTV) announced it will release its fiscal 2022 fourth quarter financial results on December 12, 2022, after market close. A conference call is scheduled for the same day at 5:00 p.m. ET to discuss the results. Interested participants can join via phone or access a live webcast through the company's investor relations page. Inotiv specializes in contract research services for drug discovery, aiming to enhance efficiency and reduce costs in the development of new drugs and medical devices.

Inotiv, a prominent contract research organization, announced that its leadership will attend several investor conferences in November 2022. Key events include the Furey Research Partners Hidden Gems Conference (November 7-8), the Jefferies Global Healthcare Conference in London (November 15-16), and the Craig-Hallum Alpha-Select Conference in New York (November 17). Robert Leasure Jr. and Beth Taylor will represent the company, providing insights into their drug discovery services. Presentation materials will be available on their website.

Inotiv, a prominent contract research organization, announced that Robert Leasure Jr. and Beth Taylor will attend two investor conferences in September 2022. The conferences include the 2022 Wells Fargo Healthcare Conference in Boston from September 7-9 and the Lake Street Capital Markets 6th Annual Best Ideas Growth Conference in New York City on September 14, 2022. Inotiv focuses on nonclinical and analytical drug discovery, aiming to enhance efficiency and reduce costs in drug development.

Inotiv, Inc. (Nasdaq: NOTV) reported significant growth in Q3 FY 2022, with revenues reaching $172.7 million, a dramatic rise from $22.9 million in Q3 FY 2021. This growth was fueled by acquisitions and increased demand in its Discovery and Safety Assessment and Research Models and Services sectors. However, the company suffered a net loss of $(3.6) million compared to a profit of $2.6 million in the prior year. Adjusted EBITDA soared to $37.0 million, and guidance for FY 2022 revenue was lifted to at least $550 million.

Inotiv, Inc. (NASDAQ: NOTV) announced the upcoming release of its fiscal 2022 third quarter financial results for the period ending June 30, 2022. The press release states that the results will be issued on August 10, 2022, after market close. A conference call is scheduled for the same day at 5:00 p.m. ET to discuss these results. Interested participants can join through provided domestic and international dial-in numbers. A webcast of the call will be available on the Inotiv website.

Inotiv (NASDAQ: NOTV) announced a significant expansion in its capacity to conduct Good Laboratory Practices (GLP) studies for in vitro cytogenetics and bacterial mutation assays. This enhancement is part of the Standard Battery of genetic toxicology studies needed for first-in-human evaluations of new therapeutics. Following the acquisition of genetic toxicology assets from MilliporeSigma in July 2021 and Integrated Laboratory Systems in January 2022, Inotiv aims to meet increasing demand and achieve full operational capacity by early 2023.

Inotiv, Inc. (NASDAQ: NOTV) announced a settlement involving Envigo and the U.S. DOJ/USDA regarding the Cumberland Facility. The court-approved settlement, dated July 15, 2022, does not impose fines and denies any admission of liability by Envigo. It includes a transfer plan for the facility's orderly closure, expected to take about 60 days. Inotiv plans to cease operations at this facility, which contributed less than 1% of total sales and has not been profitable since acquisition. This strategic decision follows prior disclosures about the need for facility improvements.

Inotiv, Inc. (NASDAQ: NOTV) has successfully acquired Protypia, Inc., a Nashville-based company specializing in protein/peptide bioanalytical services, for approximately $11 million. This acquisition, comprised of $9.5 million in cash and shares, enhances Inotiv’s capabilities in mass spectrometry and supports drug development across key areas such as immuno-oncology and gene therapy. The company aims to integrate Protypia's technology to improve clinical trial efficacy and retain all existing Protypia employees.

Inotiv, Inc. (NASDAQ: NOTV) announces the appointment of Glenn Washer as Group President, Safety Assessment, effective June 20, 2022. This new role aims to enhance the Company's safety assessment services globally. Washer, a board-certified toxicologist with over 35 years of CRO/biopharma experience, previously led initiatives at Frontage Laboratories and Charles River Laboratories. His responsibilities will focus on growing the safety assessment business, improving processes, and delivering excellent client experiences. Inotiv remains committed to advancing drug discovery and development services.